Show simple item record

dc.contributor.authorOsman, Abdullah A.
Neskey, David M.
Katsonis, Panagiotis
Patel, Ameeta A.
Ward, Alexandra M.
Hsu, Teng-Kuei
Hicks, Stephanie C.
McDonald, Thomas O.
Ow, Thomas J.
Alves, Marcus Ortega
Pickering, Curtis R.
Skinner, Heath D.
Zhao, Mei
Sturgis, Eric M.
Kies, Merrill S.
El-Naggar, Adel
Perrone, Federica
Licitra, Lisa
Bossi, Paolo
Kimmel, Marek
Frederick, Mitchell J.
Lichtarge, Olivier
Myers, Jeffrey N.
dc.date.accessioned 2017-05-15T17:23:57Z
dc.date.available 2017-05-15T17:23:57Z
dc.date.issued 2015
dc.identifier.citation Osman, Abdullah A., Neskey, David M., Katsonis, Panagiotis, et al.. "Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients." Cancer Research, 75, no. 7 (2015) AACR: 1205-1215. http://dx.doi.org/10.1158/0008-5472.CAN-14-2729.
dc.identifier.urihttps://hdl.handle.net/1911/94253
dc.description.abstract TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.
dc.language.iso eng
dc.publisher AACR
dc.rights This is an author's peer-reviewed final manuscript, as accepted by the publisher. The published article is copyrighted by AACR.
dc.title Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients
dc.type Journal article
dc.citation.journalTitle Cancer Research
dc.citation.volumeNumber 75
dc.citation.issueNumber 7
dc.type.dcmi Text
dc.identifier.doihttp://dx.doi.org/10.1158/0008-5472.CAN-14-2729
dc.identifier.pmcid PMC4615655
dc.identifier.pmid 25691460
dc.type.publication post-print
dc.citation.firstpage 1205
dc.citation.lastpage 1215


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record